CVRx Q1 revenue $4.1M (+43% YoY); US HF revenue up 133% to $2.9M

CVRx, Inc.

2022-Q1 EPS reported -$0.49 revenue$4,076,000

Net loss $10.0M ($0.49 per share) vs $8.6M loss ($23.92 per share) in Q1 2021; weighted avg shares 20.45M.
U.S. active implanting centers grew to 56 from 19; sales territories expanded to 17 from 6 year-over-year.
Cash $131.2M at Mar 31, 2022; full-year 2022 revenue guidance $20-23M; Q2 expected $4.5-5M.
Received FDA approval for new tablet-form factor programmer in April 2022.
Gross margin improved to 77% from 70%; R&D $2.3M (+29%), SG&A $10.8M (+142%).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.